HomepageProducts & ServicesNew Products > Stago Launches New Research Product for Antiplatelet Drug Testing

Stago Launches New Research Product for Antiplatelet Drug Testing

Back to list

January 2014, Parsippany, NJ, USA – Diagnostica Stago Inc. introduces Cy-Quant VASP/P2Y12 (cat # 01076) for examination of platelet responsiveness to specific platelet ADP receptor (P2Y12) antagonists and their in vitro effects in fresh human whole blood. Cy-Quant VASP/P2Y12 is an enzyme-linked immunosorbent assay (ELISA) that can be used with any plate reader reporting 450 nm wavelengths.

Cy-Quant VASP/P2Y12 is P2Y12-specific and independent of other platelet receptors. It can be used to determine the effectiveness of anti-P2Y12 drugs such as clopidogrel (Plavix®), prasugrel (Effient®), and ticagrelor (Brilinta®). Cy-Quant VASP/P2Y12 performance is not impacted by Aspirin or abciximab (ReoPro®), platelet count, or vWF levels.

Platelet responsiveness to the drug of interest is determined by exposing citrated whole blood to different platelet agonists. The intracellular vasodilator-stimulated phosphoprotein (VASP) phosphorylation level is measured and used as a surrogate biomarker for inhibited, activated or resting platelets.

Cy-Quant VASP/P2Y12 is optimized for flexible test volumes with minimal waste. Individual, break-away wells enable use of only the reagents and disposables needed to run the assay regardless of the batch size. Minimal sample volume (40 μL) is required and samples may be analyzed up to 48 hours after collection, allowing for analysis away from the original site of collection and batched runs.

With the flexibility, efficiency and reliability of the ELISA method and wide working platelet reactivity index (PRI) of 0 to 100%, Cy-Quant VASP/P2Y12 assay is an effective alternative to traditional functional assays such as platelet aggregometry.

The Cy-Quant VASP/P2Y12 kit is for research use only in the U.S. and Canada (not for use in diagnostic procedures).

About Stago Canada Ltd.

Stago Canada Ltd is the exclusive provider of the Diagnostica Stago Hemostasis product lines in Canada and offers a complete system of coagulation instruments and optimized reagent kits for routine as well as specialty analysis. Stago Canada Ltd is the Canadian subsidiary of Diagnostica Stago, S.A.S. France, a leader in the development and manufacture of Hemostasis products. For more information about any Stago product or service, please call 416-774-2478 or visit our website at www.stago-ca.com

PLAVIX is a registered trademark of Bristol-Meyers Squibb/Sanofi Pharmaceuticals Partnership. EFFIENT is a registered trademark of Eli Lilly and Company. BRILINTA is a registered trademark of the AstraZeneca group of companies. ReoPro is a registered trademark of Eli Lilly and Company.



Susan Taylor, Director of Marketing
Diagnostica Stago, Inc.
(973) 867-2042